VEGFA and colorectal cancer: Bevacizumab, a monoclonal antibody that inhibits angiogenesis by blocking vascular endothelial growth factor (VEGF), has also been implicated as a cause of PRES, particularly in patients with renal and colorectal cancer [95,96].